Does J3473 require prior authorization?

No, J3473 does not require prior authorization (high confidence). Covered without prior authorization.

What is the Medicare reimbursement rate for J3473?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`J3473`, Injection, hyaluronidase, recombinant, 1 usp unit

HCPCS/CPT

Prior Authorization

No Prior Auth Required

Covered without prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

For repeat procedures beyond specified intervals (e.g., beyond 12 months), submission of clinical review documentation justifying continued treatment.
For oncologic, infectious, or complex structural indications: relevant pathology/imaging reports, operative reports, prior treatments, and specialist consultation notes as applicable to demonstrate meeting of selection criteria.

For facet joint injections: documentation that member has symptoms suggestive of facet joint syndrome (absence of radiculopathy, pain aggravated by extension/rotation/lateral bending, not typically associated with neurological deficits), provocative testing on physical exam confirming facet mediated pain (pain exacerbated by extension and rotation), imaging studies ruling out other obvious causes (e.g., fracture, tumor, infection, significant extraspinal lesion), pain limits ADLs, pain duration > 3 months, and pain persisted despite ≥ 6 weeks of conservative treatment (systemic meds and/or PT).

For trigger point injections: documentation that conservative treatments (bed rest, exercises, heat/cold, massage, pharmacotherapies including NSAIDs, muscle relaxants, non-narcotic analgesics) were tried and failed; symptoms persisted > 3 months; trigger points identified by palpation; injections are part of a comprehensive pain management program (PT, education, psychosocial support, oral meds where appropriate); recording of number of sets administered and timing (no repeats > every 7 days during diagnostic phase; after diagnosis, typically no more frequent than once every 2 months; repeated treatment beyond 12 months requires review).

Key Coverage Criteria

Epiduroscopy / epidural lysis of adhesions: proposed for diagnosis/treatment of intractable LBP (including failed back surgery syndrome) by visualizing and lysing adhesions and injecting medications (insufficient high-quality evidence to support routine clinical use).
Kyphoplasty (balloon-assisted vertebroplasty): restore bone height for painful osteoporotic compression fractures (OVCFs); NICE and other assessments note kyphoplasty may be a reasonable alternative to vertebroplasty for recent fractures.
Sacropasty: injection of PMMA into sacrum for sacral insufficiency fractures (SIFs) in osteoporotic patients to stabilize fracture and relieve pain (developing indication).
Vesselplasty: image-guided procedure using a containment device and PMMA to treat symptomatic vertebral compression fractures to reduce cement leakage (investigational/promise shown but limited evidence).
Microsurgical anterior foraminotomy: proposed for intractable cervical radiculopathy to remove herniated disc or bone spur via anterior approach without fusion (insufficient high-quality evidence).
Open sacroiliac fusion: proposed for SIJ dysfunction/syndrome when other non-operative treatments failed; evidence insufficient to support routine use.

`J3473`, Injection, hyaluronidase, recombinant, 1 usp unit

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

2 Active Policies

Related Codes

Have a follow-up question?

J3473, Injection, hyaluronidase, recombinant, 1 usp unit

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

2 Active Policies

Related Codes

Have a follow-up question?

`J3473`, Injection, hyaluronidase, recombinant, 1 usp unit